Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Jenny Lee"'
Publikováno v:
Nursing Ethics. 28:1010-1025
Background: Serious Illness Conversations aim to discuss patient goals. However, on acute medicine units, seriously ill patients may undergo distressing interventions until death. Objectives: To investigate the feasibility of using the Surprise Quest
Publikováno v:
Annals of Palliative Medicine. 9:1296-1306
The world of oncology treatment is rapidly changing, and with the investigation into and utilization of molecular signaling pathways for cancer treatment, many new targeted small-molecule oral agents have been introduced as therapies, with more new d
Autor:
Jenny Lee, Maarten E. Tushuizen, Quentin M. Anstee, Adriaan G. Holleboom, Yasaman Vali, M. Julia Brosnan, Mohammad Hadi Zafarmand, Max Nieuwdorp, Patrick M.M. Bossuyt, Anne-Marieke van Dijk, Anne Linde Mak
Publikováno v:
Journal of Clinical Medicine, 10(13). MDPI
Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 10, Iss 2910, p 2910 (2021)
Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 10, Iss 2910, p 2910 (2021)
Early detection of liver fibrosis is crucial to select the correct care path for patients with non-alcoholic fatty liver disease (NAFLD). Here, we systematically review the evidence on the performance of FibroMeter versions in detecting different lev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16eb45c37d1a7b451b87234c320c62ea
http://hdl.handle.net/1887/3203806
http://hdl.handle.net/1887/3203806
Autor:
Patrick M.M. Bossuyt, René Spijker, Mohammad Hadi Zafarmand, Jérôme Boursier, Quentin M. Anstee, Jenny Lee, Yasaman Vali
Publikováno v:
Liver international, 41(2), 261-270. Wiley-Blackwell
Liver International
Liver International, Wiley-Blackwell, 2021, 41 (2), pp.261-270. ⟨10.1111/liv.14669⟩
Liver International
Liver International, Wiley-Blackwell, 2021, 41 (2), pp.261-270. ⟨10.1111/liv.14669⟩
Background & Aims Fibrosis is the strongest predictor for long‐term clinical outcomes among patients with non‐alcoholic fatty liver disease (NAFLD). There is growing interest in employing non‐invasive methods for risk stratification based on pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25c090f9583ab318fd95bfc95c3dad6d
https://pure.amc.nl/en/publications/prognostic-accuracy-of-fib4-nafld-fibrosis-score-and-apri-for-nafldrelated-events-a-systematic-review(f719bc9a-94ff-4374-aa18-57fce58a7f8b).html
https://pure.amc.nl/en/publications/prognostic-accuracy-of-fib4-nafld-fibrosis-score-and-apri-for-nafldrelated-events-a-systematic-review(f719bc9a-94ff-4374-aa18-57fce58a7f8b).html
Autor:
Warren D. Foltz, Alejandro Berlin, Peter Chung, Timothy J. Craig, Cynthia Ménard, Jenny Lee, Sangjune Laurence Lee
Publikováno v:
Physics and Imaging in Radiation Oncology
Physics and Imaging in Radiation Oncology, Vol 9, Iss, Pp 1-6 (2019)
Physics and Imaging in Radiation Oncology, Vol 9, Iss, Pp 1-6 (2019)
Background and purpose: Dose escalation has improved cancer outcomes for patients with localized prostate cancer. Targeting subprostatic tumor regions for dose intensification may further improve outcomes. Apparent Diffusion Coefficient (ADC) maps ma
Autor:
Alejandro Berlin, Charles Catton, Peter Chung, Timothy J. Craig, Aravindhan Sundaramurthy, Alexandra Rink, Cynthia Ménard, Mary Gospodarowicz, Noelia Sanmamed, Bernadeth Lao, Eshetu Astenafu, Andrew Bayley, Warren D. Foltz, Jenny Lee, Sangeet Ghai, Andrew McPartlin, Padraig Warde
Publikováno v:
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 149
To report dosimetry, preliminary toxicity and health-related quality of life (HRQoL) outcomes of tumor-targeted dose-escalation delivered by integrated boost volumetric arc therapy (IB-VMAT) or MR-guided HDR brachytherapy (HDR) boost for prostate can
Autor:
Quentin M. Anstee, Yasaman Vali, Patrick M.M. Bossuyt, Kevin L. Duffin, Jenny Lee, M. Julia Brosnan, Mohammad Hadi Zafarmand, Jérôme Boursier, Koos H. Zwinderman, Joanne Verheij
Publikováno v:
PLoS ONE, Vol 15, Iss 9 (2020)
PLoS ONE, Vol 15, Iss 9, p e0238717 (2020)
PLoS ONE
PLoS ONE, Public Library of Science, 2020, 15 (9), pp.e0238717. ⟨10.1371/journal.pone.0238717⟩
PLoS ONE, 15(9 September):e0238717. Public Library of Science
PLOS ONE
PLoS ONE, Vol 15, Iss 9, p e0238717 (2020)
PLoS ONE
PLoS ONE, Public Library of Science, 2020, 15 (9), pp.e0238717. ⟨10.1371/journal.pone.0238717⟩
PLoS ONE, 15(9 September):e0238717. Public Library of Science
PLOS ONE
IntroductionAssociation between elevated cytokeratin 18 (CK-18) levels and hepatocyte death has made circulating CK-18 a candidate biomarker to differentiate non-alcoholic fatty liver from non-alcoholic steatohepatitis (NASH). Yet studies produced va
Publikováno v:
BMC Complementary and Alternative Medicine, Vol 19, Iss 1, Pp 1-7 (2019)
BMC Complementary and Alternative Medicine
BMC Complementary and Alternative Medicine
Background The use of Complementary Medicines (CMs) has significantly increased in Australia over the last decade. This study attempts to determine the extent to which complementary and alternative medicines are recorded, ceased or initiated in the a
Autor:
Jose F. Ponte, Katharine C. Lai, Meghan E. Kelly, Angela Romanelli, Surina Sikka, Callum M. Sloss, Stuart W. Hicks, L. Cristina Gavrilescu, Prerak Shah, Jenny Lee, Yong Yi, Leanne Lanieri
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 19, Iss 9, Pp 661-671 (2017)
Neoplasia (New York, N.Y.)
Neoplasia (New York, N.Y.)
Naratuximab emtansine (IMGN529) is an investigational antibody-drug conjugate consisting of a CD37-targeting antibody conjugated to the maytansine-derived microtuble disruptor, DM1. IMGN529 has shown promising preclinical and clinical activity in non
Autor:
Xiaoxiao Wang, Bin Liu, Sheng Li Xue, Jin Zhou, Songbai Liu, Hesham M. Amin, Chao Wang, Yao-Hua Song, Yangxin Li, Yunliang Wang, Yufeng Xie, Congcong Shen, Jenny Lee Song, Zaixiang Tang, Weichang Chen
Publikováno v:
Oncotarget
// Congcong Shen 1, * , Yao-Hua Song 1, * , Yufeng Xie 2, * , Xiaoxiao Wang 1, * , Yunliang Wang 3, * , Chao Wang 4, * , Songbai Liu 5 , Sheng-Li Xue 6 , Yangxin Li 7 , Bin Liu 8 , Zaixiang Tang 9 , Weichang Chen 4 , Jenny Song 1 , Hesham M. Amin 10